rs1343637666

Positions:

• chr7-30609715-G-A

Variant summary

Our verdict is Likely benign. Variant got -4 ACMG points: 0P and 4B. BS2

The NM_002047.4(GARS1):​c.866G>A​(p.Gly289Glu) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000479 in 1,461,384 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Uncertain significance (★).

• Frequency:
  • Genomes: not found (cov: 33)
  • Exomes 𝑓: 0.0000048 (0 hom.)
• Consequence: GARS1 NM_002047.4 missense
• Clinical Significance: Uncertain significance criteria provided, single submitter U:1
• Conservation: PhyloP100: 7.98

Genes affected

GARS1 (HGNC:4162): (glycyl-tRNA synthetase 1) This gene encodes glycyl-tRNA synthetase, one of the aminoacyl-tRNA synthetases that charge tRNAs with their cognate amino acids. The encoded enzyme is an (alpha)2 dimer which belongs to the class II family of tRNA synthetases. It has been shown to be a target of autoantibodies in the human autoimmune diseases, polymyositis or dermatomyositis. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Oct 2015]

GARS1 (HGNC:):

ACMG classification

Verdict is Likely_benign. Variant got -4 ACMG points.

• BS2: High AC in GnomAdExome4 at 7 AD gene.

Transcripts

RefSeq

Gene	Transcript	HGVSc	HGVSp	Effect	#exon/exons	MANE	Protein	UniProt
GARS1	NM_002047.4	c.866G>A	p.Gly289Glu	missense_variant	7/17	ENST00000389266.8	NP_002038.2
GARS1	NM_001316772.1	c.704G>A	p.Gly235Glu	missense_variant	7/17		NP_001303701.1

Ensembl

Gene	Transcript	HGVSc	HGVSp	Effect	#exon/exons	TSL	MANE	Protein	Appris	UniProt
GARS1	ENST00000389266.8	c.866G>A	p.Gly289Glu	missense_variant	7/17	1	NM_002047.4	ENSP00000373918.3
GARS1	ENST00000675651.1	c.866G>A	p.Gly289Glu	missense_variant	7/17			ENSP00000502513.1
GARS1	ENST00000675810.1	c.764G>A	p.Gly255Glu	missense_variant	6/16			ENSP00000502743.1
GARS1	ENST00000675693.1	c.698G>A	p.Gly233Glu	missense_variant	8/18			ENSP00000502174.1
GARS1	ENST00000675051.1	c.665G>A	p.Gly222Glu	missense_variant	7/17			ENSP00000502296.1
GARS1	ENST00000674815.1	c.497G>A	p.Gly166Glu	missense_variant	7/17			ENSP00000502799.1
GARS1	ENST00000674851.1	c.497G>A	p.Gly166Glu	missense_variant	8/18			ENSP00000502451.1
GARS1	ENST00000444666.6	n.866G>A		non_coding_transcript_exon_variant	7/18	3		ENSP00000415447.2
GARS1	ENST00000674616.1	n.*580G>A		non_coding_transcript_exon_variant	8/18			ENSP00000502408.1
GARS1	ENST00000674643.1	n.866G>A		non_coding_transcript_exon_variant	7/17			ENSP00000501636.1
GARS1	ENST00000674737.1	n.*204G>A		non_coding_transcript_exon_variant	8/18			ENSP00000502464.1
GARS1	ENST00000674807.1	n.866G>A		non_coding_transcript_exon_variant	7/16			ENSP00000502814.1
GARS1	ENST00000675529.1	n.*736G>A		non_coding_transcript_exon_variant	8/18			ENSP00000501655.1
GARS1	ENST00000675859.1	n.866G>A		non_coding_transcript_exon_variant	7/15			ENSP00000502033.1
GARS1	ENST00000676088.1	n.*808G>A		non_coding_transcript_exon_variant	9/19			ENSP00000501884.1
GARS1	ENST00000676140.1	n.866G>A		non_coding_transcript_exon_variant	7/17			ENSP00000502571.1
GARS1	ENST00000676164.1	n.*317G>A		non_coding_transcript_exon_variant	7/17			ENSP00000501986.1
GARS1	ENST00000676210.1	n.*155G>A		non_coding_transcript_exon_variant	8/18			ENSP00000502373.1
GARS1	ENST00000676259.1	n.*298G>A		non_coding_transcript_exon_variant	7/17			ENSP00000501980.1
GARS1	ENST00000676403.1	n.866G>A		non_coding_transcript_exon_variant	7/16			ENSP00000502681.1
GARS1	ENST00000674616.1	n.*580G>A		3_prime_UTR_variant	8/18			ENSP00000502408.1
GARS1	ENST00000674737.1	n.*204G>A		3_prime_UTR_variant	8/18			ENSP00000502464.1
GARS1	ENST00000675529.1	n.*736G>A		3_prime_UTR_variant	8/18			ENSP00000501655.1
GARS1	ENST00000676088.1	n.*808G>A		3_prime_UTR_variant	9/19			ENSP00000501884.1
GARS1	ENST00000676164.1	n.*317G>A		3_prime_UTR_variant	7/17			ENSP00000501986.1
GARS1	ENST00000676210.1	n.*155G>A		3_prime_UTR_variant	8/18			ENSP00000502373.1
GARS1	ENST00000676259.1	n.*298G>A		3_prime_UTR_variant	7/17			ENSP00000501980.1

Frequencies

GnomAD3 genomes Cov.: 33

GnomAD3 exomes AF: 0.00000401 AC: 1 AN: 249370 Hom.: 0 AF XY: 0.00 AC XY: 0 AN XY: 135288

Gnomad AFR exome AF: 0.00

Gnomad AMR exome AF: 0.00

Gnomad ASJ exome AF: 0.00

Gnomad EAS exome AF: 0.00

Gnomad SAS exome AF: 0.00

Gnomad FIN exome AF: 0.00

Gnomad NFE exome AF: 0.00000884

Gnomad OTH exome AF: 0.00

GnomAD4 exome AF: 0.00000479 AC: 7 AN: 1461384 Hom.: 0 Cov.: 30 AF XY: 0.00000275 AC XY: 2 AN XY: 727006

Gnomad4 AFR exome AF: 0.00

Gnomad4 AMR exome AF: 0.00

Gnomad4 ASJ exome AF: 0.00

Gnomad4 EAS exome AF: 0.00

Gnomad4 SAS exome AF: 0.00

Gnomad4 FIN exome AF: 0.00

Gnomad4 NFE exome AF: 0.00000630

Gnomad4 OTH exome AF: 0.00

GnomAD4 genome Cov.: 33

Alfa AF: 0.0000712 Hom.: 0

ClinVar

Significance: Uncertain significance

Submissions summary: Uncertain:1

Revision: criteria provided, single submitter

Submissions by phenotype

Charcot-Marie-Tooth disease type 2 Uncertain:1

Uncertain significance, criteria provided, single submitter

clinical testing

Labcorp Genetics (formerly Invitae), Labcorp

Nov 19, 2022

ClinVar contains an entry for this variant (Variation ID: 476763). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt GARS protein function. This variant has not been reported in the literature in individuals affected with GARS-related conditions. This variant is present in population databases (no rsID available, gnomAD 0.0008%). This sequence change replaces glycine, which is neutral and non-polar, with glutamic acid, which is acidic and polar, at codon 289 of the GARS protein (p.Gly289Glu). -

Computational scores

Source: dbNSFP v4.3

Name	Calibrated prediction	Score	Prediction
AlphaMissense	Pathogenic	0.57
BayesDel_addAF	Uncertain	0.12	D
BayesDel_noAF	Uncertain	-0.070
CADD	Uncertain	26
DANN	Uncertain	0.99
DEOGEN2	Benign	0.16	T
Eigen	Benign	0.13
Eigen_PC	Uncertain	0.34
FATHMM_MKL	Pathogenic	0.99	D
LIST_S2	Pathogenic	0.99	D
M_CAP	Benign	0.069	D
MetaRNN	Uncertain	0.46	T
MetaSVM	Benign	-0.63	T
PrimateAI	Pathogenic	0.80	T
PROVEAN	Benign	-1.5	N
REVEL	Uncertain	0.34
Sift	Benign	0.15	T
Sift4G	Benign	0.18	T
Polyphen		0.041	B
Vest4		0.68
MutPred		0.41		Gain of solvent accessibility (P = 0.012);
MVP		0.52
MPC		1.3
ClinPred		0.62	D
GERP RS		5.5
Varity_R		0.50
gMVP		0.75

Splicing

Name	Calibrated prediction	Score	Prediction
SpliceAI score (max)		0.0		Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Other links and lift over

dbSNP: rs1343637666; hg19: chr7-30649331;